Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,880.30 +1,770.32 (+2.72%) CMC Crypto 200
1,366.31 -7.54 (-0.55%)
bluebird bio, Inc. (0HOH.L)
| Previous close | 1.0400 |
| Open | 1.0400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.0300 - 1.0600 |
| 52-week range | 0.8856 - 5.5280 |
| Volume | |
| Avg. volume | 57,271 |
| Market cap | 577,473 |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., May 09, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress.
- Business Wire
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET.
- Business Wire
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events. LYFGENIA was approved by the FDA in December 2023 and is the most deeply studied gene therapy for sickle cell disease, with the longest follow-up in the field.
